Agomelatine in the treatment of fibromyalgia: A 12-week, open-label, uncontrolled preliminary study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 507-511

  Bruno, Antonio ^a   Micò, Umberto ^a   Lorusso, Simona ^a   Cogliandro, Nadia ^a   Pandolfo, Gianluca ^a   Caminiti, Maurizio ^b   Zoccali, Rocco A ^a   Muscatello, Maria R A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Bianchi Melacrino Morelli Hospital   (Italy)

Author keywords

agomelatine; anxiety; cognition; depression; fibromyalgia

Indexed keywords

AGOMELATINE;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITION; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FEMALE; FIBROMYALGIA; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HEART RATE; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; STROOP TEST; TREATMENT DURATION; VISUAL ANALOG SCALE; WISCONSIN CARD SORTING TEST; ZUNG SELF RATING DEPRESSION SCALE; ZUNG SELF-RATING ANXIETY SCALE;

ACETAMIDES; AFFECT; ANALGESICS; ANTIDEPRESSIVE AGENTS; ANXIETY; CHRONIC PAIN; COGNITION; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; FIBROMYALGIA; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879839518     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829057ae     Document Type: Article

References (36)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum. 1990;36:160-172.
2. McBeth J, Mulvey MR. Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nat Rev Rheumatol. 2012;8:108-116.
3. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010; 39:448-453.
4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age of onset distributions of DSM IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
5. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67:1219-1225.
6. Nicholl BI, MacFarlane GJ, Davies KA, et al. Premorbid psychosocial factors are associated with poor health-related quality of life in subjects with new onset of chronic widespread painVresults from the EPIFUND study. Pain. 2009;141:119-126.
7. Stahl SM. Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes. J Clin Psychiatry. 2003;64:863-864.
8. Dadabhoy D, Clauw DJ. Therapy Insight: fibromyalgiaVa different type of pain needing a different type of treatment. Nat Clin Pract Rheumatol. 2006;2:364-372.
9. Gormsen L, Rosenberg R, Bach FW, et al. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14:127.e1-127.e8.
10. Wikner J, Hirsch U, Wetterberg L, et al. FibromyalgiaVa syndrome with decreased nocturnal melatonin secretion. Clin Endocrinol. 1998;49:179-183.
11. Katz RS, Heard AR, Mills M, et al. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol. 2004;10:53-58.
12. Bennett RM, Jones J, Turk DC, et al. An Internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
13. Glass JM. Fibromyalgia and cognition. J Clin Psychiatry. 2008;69(suppl 2):20-24.
14. Suhr JA. Neuropsychological impairment in fibromyalgia: relation to depression, fatigue, and pain. J Psychosom Res. 2003;55:321-329.
15. Häuser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301:198-209.
16. Hussain SA, Al-Khalifa II, Jasim NA, et al. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res. 2011;50:267-271.
17. Thymanax\, Valdoxan\: European Public Assessment Report EPAR-EMA. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/ human/000916/WC500038315.pdf. Access February 11, 2010.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
20. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
21. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics. 1971;12:371-379.
22. Huskisson EC. Visual analog scales. In: Melzack R. Pain Measurement and Assessment. New York, NY: Raven; 1983:33-37.
23. Ferrans CE, Powers MJ. Quality of life index: development and psychometric properties. ANS Adv Nurs Sci. 1985;8:15-24.
24. Heaton RK, Chelune GI, Talley JL, et al. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993.
25. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. 3rd ed. Iowa City, IA: AJA Associates; 1983.
26. Trenerry MR, Crosson B, DeBoe J, et al. Stroop Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources, Inc; 1989.
27. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115-1122.
28. Wilhelmsen M, Amirian I, Reiter RJ, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011;51(3):270-277.
29. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474.
30. van Middendorp H, Lumley MA, Jacobs JWG, et al. Emotions and emotional approach and avoidance strategies in fibromyalgia. J Psychosom Res. 2008;64:159-167.
31. Hsu MC, Schubiner H, Lumley MA, et al. Sustained pain reduction through affective self-awareness in fibromyalgia: a randomized controlled trial. J Gen Intern Med. 2010;25: 1064-1070.
32. Enns MW, Larsen DK, Cox BJ. Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord. 2000;60:33-41.
33. Rush AJ, Hiser W, Giles DE. A comparison of self- reported versus clinician-related symptoms in depression. J Clin Psychiatry. 1987;48:246-248.
34. Rodríguez-Andreu J, Ibáñez-Bosch R, Portero-Vázquez A, et al. Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. BMC Musculoskelet Disord. 2009;21:162.
35. McAllister-Williams RH, Baldwin DS, Haddad PM, et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010;25:95-102.
36. Fornaro M, Prestia D, Colicchio S et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287-304.